Studies have demonstrated that HHT markedly enhances the anti-myeloma efficacy of BTZ in both in vitro multiple myeloma (MM) cell models and in vivo mouse xenotransplantation models through inhibition of the NF-κB signaling pathway (48). Here, CASC3 is linked to plasma cell myeloma.